Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q99959: Variant p.Ser140Phe

Plakophilin-2
Gene: PKP2
Feedback?
Variant information Variant position: help 140 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Serine (S) to Phenylalanine (F) at position 140 (S140F, p.Ser140Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 140 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 881 The length of the canonical sequence.
Location on the sequence: help EGRWGRGTAQYSSQKSVEER S LRHPLRRLEISPDSSPERAH The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 881 Plakophilin-2
Region 1 – 360 Required for binding to single-stranded DNA
Region 1 – 348 Required for interaction with influenza A virus RNA polymerase subunit PB1
Modified residue 132 – 132 Phosphoserine
Modified residue 135 – 135 Phosphoserine
Modified residue 151 – 151 Phosphoserine
Modified residue 154 – 154 Phosphoserine
Modified residue 155 – 155 Phosphoserine



Literature citations
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy.
Gerull B.; Heuser A.; Wichter T.; Paul M.; Basson C.T.; McDermott D.A.; Lerman B.B.; Markowitz S.M.; Ellinor P.T.; MacRae C.A.; Peters S.; Grossmann K.S.; Michely B.; Sasse-Klaassen S.; Birchmeier W.; Dietz R.; Breithardt G.; Schulze-Bahr E.; Thierfelder L.;
Nat. Genet. 36:1162-1164(2004)
Cited for: VARIANTS ARVD9 PHE-615; GLN-654 AND ARG-796; VARIANT PHE-140; Comprehensive desmosome mutation analysis in North Americans with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
den Haan A.D.; Tan B.Y.; Zikusoka M.N.; Llado L.I.; Jain R.; Daly A.; Tichnell C.; James C.; Amat-Alarcon N.; Abraham T.; Russell S.D.; Bluemke D.A.; Calkins H.; Dalal D.; Judge D.P.;
Circ. Cardiovasc. Genet. 2:428-435(2009)
Cited for: VARIANTS ARVD9 SER-424 AND PHE-787; VARIANTS ASN-26; ILE-70; PHE-140; VAL-195; SER-276; PRO-366; PRO-372; MET-526; SER-531 AND ILE-587; Missense variants in plakophilin-2 in arrhythmogenic right ventricular cardiomyopathy patients -- disease-causing or innocent bystanders?
Christensen A.H.; Benn M.; Tybjaerg-Hansen A.; Haunso S.; Svendsen J.H.;
Cardiology 115:148-154(2010)
Cited for: VARIANTS ARVD9 LYS-62; 79-ARG--ASP-881 DEL; ARG-489 AND VAL-673; VARIANTS ASN-26; ASP-58; ILE-70; PHE-140; ALA-338; PRO-366; SER-531 AND ILE-587;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.